2-ethyl-1-[(1R)-1-phenylethyl]-1H-imidazole | 850648-91-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-ethyl-1-[(1R)-1-phenylethyl]-1H-imidazole
• 英文别名: 2-ethyl-1-[(1R)-1-phenylethyl]imidazole
• CAS: 850648-91-8
• 化学式: C₁₃H₁₆N₂
• 分子量: 200.283
• InChiKey: ZNTLGOFGCBMXFE-LLVKDONJSA-N

物化性质

• 沸点：
  317.1±11.0 °C(Predicted)
• 密度：
  1.00±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-溴戊烷 、 2-ethyl-1-[(1R)-1-phenylethyl]-1H-imidazole 以 三氯乙烷 为溶剂， 反应 72.0h， 以91%的产率得到2-ethyl-3-pentyl-1-[(1R)-1-phenylethyl]-1H-imidazolium bromide
  参考文献：
  名称：

  New chiral imidazolinic derivatives

  摘要：

  Novel C-2 substituted 4,5-dihydroimidazoles and imidazoles bearing an N-linked stereogenic group were rapidly prepared from a chiral primary amine. Quaternization of these derivatives resulted in a range of scalemic room temperature ionic liquids. The ability of the imidazolium species to act as reaction medium and/or phase transfer catalyst was also assessed. (C) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2005.01.014
• 作为产物：
  描述：

  (R)-N-(1-phenylethyl)ethane-1,2-diamine 在 barium permanganate 、 4 A molecular sieve 、 溶剂黄146 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 21.0h， 生成 2-ethyl-1-[(1R)-1-phenylethyl]-1H-imidazole
  参考文献：
  名称：

  New chiral imidazolinic derivatives

  摘要：

  Novel C-2 substituted 4,5-dihydroimidazoles and imidazoles bearing an N-linked stereogenic group were rapidly prepared from a chiral primary amine. Quaternization of these derivatives resulted in a range of scalemic room temperature ionic liquids. The ability of the imidazolium species to act as reaction medium and/or phase transfer catalyst was also assessed. (C) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2005.01.014

文献信息

• Pharmaceutical compositions and methods for anesthesiological applications
  申请人：Melt Pharmaceuticals, Inc.

  公开号：US10391102B2

  公开（公告）日：2019-08-27

  Pharmaceutical compositions and methods for inducing conscious sedation using such compositions are described, the compositions comprising a benzodiazepine-based compound, a NMDA antagonist, and optionally a β-blocker, antiemetic, an NSAID, and/or an antihistamine medication. Methods for fabricating the compositions and using them for anesthesiological applications are also described.

  描述了使用此类组合物诱导清醒镇静的药物组合物和方法，组合物包括苯二氮卓类化合物、NMDA拮抗剂，以及可选的β-受体阻滞剂、止吐药、非甾体抗炎药和/或抗组胺药物。此外，还介绍了制造这些组合物并将其用于麻醉学应用的方法。
• PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS
  申请人：IMPRIMIS PHARMACEUTICALS, INC.

  公开号：US20180271877A1

  公开（公告）日：2018-09-27

  Pharmaceutical compositions and methods for inducing conscious sedation using such compositions are described, the compositions comprising a benzodiazepine-based compound, a NMDA antagonist, and optionally a β-blocker, antiemetic, an NSAID, and/or an antihistamine medication. Methods for fabricating the compositions and using them for anesthesiological applications are also described.